Look at your course colleagues’ responses.
From your advanced practice mindset
Look at your course colleagues’ responses.
From your advanced practice mindset reflect on a discussion you would like to have with two of your course colleagues about their responses.
Post a response individually to each of them that expresses your advanced practice nursing role perspective of the data represented in their response.
DOI reference link
Use scholarly resources relevant to your advanced practice nursing role to support the key elements of the peer discussions you construct. [For example you are a family nurse practitioner what are your observations about the non-conventional modality presented in the schemata, can you locate any evidence or the foundational basic sciences that support the modality, etc?
Please be sure to validate your opinions and ideas with citations and references in APA format.
PLEASE RESPOND TO THE FOLLOWING POST:
Myocardial infarctions are commonly caused by the occlusion of a coronary artery. This occlusion then leads to ischemia and necrosis of myocardial tissue. The pathophysiological sequence following an MI can lead to developing of left ventricular failure. During an MI, myocardial tissue creates irreversible damage due to ischemia. Scar tissue develops after the ischemia, which compromises the heart’s ability to contract. The scar tissue then leads to impaired systolic function. Initially, the heart tries to compensate such as increased heart rate and the activation of the sympathetic nervous system. However, these mechanisms can lead to further myocardial stress. As LV dysfunction progresses, the heart may fail to adequately eject blood. Heart failure then can cause pulmonary congestion and edema. In summary, the pathophysiological progression from MI to LV failure involves myocardial damage, compensatory responses, and ultimately remodeling leading to impaired cardiac function and heart failure.
Several factors that can affect the severity of LV failure a following an MI. The size and location of the infarcted area determine the degree of myocardial dysfunction and LV failure. Early therapy (e.g., thrombolytics, percutaneous coronary intervention) can limit myocardial damage and improve LV function. Comorbidities such as hypertension, diabetes, and chronic kidney disease can exacerbate LV dysfunction post-MI. Older age and a family history of cardiovascular disease may contribute to poorer outcomes and increased severity of LV failure. Compliance with medications such as beta-blockers, ACE inhibitors, and diuretics.
After reviewing the CDC article and video regarding blood clots. The diagnosis of DVT or PE requires special tests that can only be performed by a doctor. Medication is used to treat DVT. Compression stockings (also called graduated compression stockings) are sometimes recommended to prevent DVT and relieve pain and swelling. Immediate medical attention is necessary to treat PE. In cases of severe, life-threatening PE, there are medicines called thrombolytics that can dissolve the clot. Other medicines, called anticoagulants, may be prescribed to prevent more clots from forming. Some people may need to be on medication long-term to prevent future blood clots.
Citations
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., … & Virani, S. S. (2019). Heart disease and stroke statistics—2019 update: a report from the American Heart Association. Circulation, 139(10), e56-e528. doi:10.1161/CIR.0000000000000659
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G., Coats, A. J., … & Filippatos, G. (2016). 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37(27), 2129-2200. doi:10.1093/eurheartj/ehw128
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Colvin, M. M., … & Wilkoff, B. L. (2017). 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation, 136(6), e137-e161. doi:10.1161/CIR.0000000000000509